Detalhe da pesquisa
1.
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Mol Cell Proteomics
; 20: 100136, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34391887
2.
Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Mol Cell Proteomics
; 18(4): 622-641, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30617155
3.
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Mol Cell Proteomics
; 16(5): 891-910, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331001
4.
Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
Cancer Res Commun
; 4(2): 337-348, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38276867
5.
A spatial map of hepatic mitochondria uncovers functional heterogeneity shaped by nutrient-sensing signaling.
Nat Commun
; 15(1): 1799, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418824
6.
A spatial map of hepatic mitochondria uncovers functional heterogeneity shaped by nutrient-sensing signaling.
bioRxiv
; 2023 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37333328
7.
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance.
Cancers (Basel)
; 15(8)2023 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37190191
8.
LKB1 acts as a critical brake for the glucagon-mediated fasting response.
Hepatol Commun
; 6(8): 1949-1961, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357082
9.
Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma.
Hepatology
; 52(6): 2034-43, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21105107
10.
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma.
Oncogene
; 40(18): 3331-3346, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33850265
11.
Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Cancer Res
; 81(11): 3051-3066, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33727228
12.
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
Cancers (Basel)
; 13(13)2021 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34283064
13.
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Cell Rep Med
; 1(1)2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32483558
14.
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Cell Rep
; 26(10): 2651-2666.e6, 2019 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30840888
15.
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Oncotarget
; 7(34): 54137-54156, 2016 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27494838
16.
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Cold Spring Harb Mol Case Stud
; 2(6): a001263, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27900369
17.
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Cancer Discov
; 5(5): 534-49, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25735773
18.
Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma.
Cancer Genomics Proteomics
; 11(1): 1-12, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24633315